TARS

Tarsus Pharmaceuticals, Inc.

Name: Tarsus Pharmaceuticals, Inc. insider trading (SEC Form 4) history
Creator: U.S. Securities and Exchange Commission

SEC CIK 1819790

$61.86 −0.2% · 90 days

90-day buys

0 open-market

90-day sells

$2.34M

8 open-market

Net insider flow

−$2.34M

Net selling

Filings shown

107

Most recent

At a glance

Over the last 90 days, insiders at TARS have sold a net $2.34M of stock (0 open-market buys vs 8 sells).

Largest recent trade: Rtw Investments, Lp sold $13.49M of TARS, trimming their stake 18%.

Most active filer: Azamian Bobak R., with 51 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for TARS, newest first

View on SEC EDGAR ↗

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Nov 17, 2023

Azamian Bobak R. sold $3.9K of TARS.

−$3.9K

200 sh @ $19

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Oct 20, 2023 ΔOwn −0.9%

Azamian Bobak R. sold $105.9K of TARS, trimming their stake 1%.

−$105.9K

8,000 sh @ $13

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Sep 22, 2023 ΔOwn −0.9%

Azamian Bobak R. sold $137.7K of TARS, trimming their stake 1%.

−$137.7K

8,000 sh @ $17

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Aug 25, 2023 ΔOwn −0.9%

Azamian Bobak R. sold $137.8K of TARS, trimming their stake 1%.

−$137.8K

8,000 sh @ $17

TARS

Tarsus Pharmaceuticals, Inc.

Buy Lin Elizabeth Yeu · Director · Open-market purchase · filed Aug 17, 2023 ΔOwn +149%

Lin Elizabeth Yeu, TARS's Director, spent $159.7K of their own money on 9,506 shares at $17, growing their stake 149%.

+$159.7K

9,506 sh @ $17

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Jul 21, 2023 ΔOwn −0.4%

Azamian Bobak R. sold $80.5K of TARS.

−$80.5K

4,174 sh @ $19

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Jul 21, 2023 ΔOwn −9.9%

Azamian Bobak R. sold $2M of TARS, trimming their stake 10%.

−$2M

99,726 sh @ $20

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Jul 14, 2023 ΔOwn −0.9%

Azamian Bobak R. sold $156.2K of TARS, trimming their stake 1%.

−$156.2K

9,000 sh @ $17

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Jun 23, 2023 ΔOwn −0.8%

Azamian Bobak R. sold $149K of TARS, trimming their stake 1%.

−$149K

8,000 sh @ $19

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Jun 16, 2023 ΔOwn −0.9%

Azamian Bobak R. sold $167.2K of TARS, trimming their stake 1%.

−$167.2K

9,000 sh @ $19

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed May 19, 2023 ΔOwn −0.8%

Azamian Bobak R. sold $127.2K of TARS, trimming their stake 1%.

−$127.2K

8,000 sh @ $16

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed May 12, 2023 ΔOwn −0.8%

Azamian Bobak R. sold $151.2K of TARS, trimming their stake 1%.

−$151.2K

9,000 sh @ $17

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed May 2, 2023 ΔOwn −0.5%

Azamian Bobak R. sold $88.2K of TARS, trimming their stake 1%.

−$88.2K

5,841 sh @ $15

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed May 2, 2023 ΔOwn −0.4%

Azamian Bobak R. sold $64.7K of TARS.

−$64.7K

4,278 sh @ $15

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Apr 25, 2023 ΔOwn −0.2%

Azamian Bobak R. sold $34.7K of TARS.

−$34.7K

2,311 sh @ $15

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Apr 21, 2023 ΔOwn −0.7%

Azamian Bobak R. sold $108.8K of TARS, trimming their stake 1%.

−$108.8K

8,000 sh @ $14

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Mar 23, 2023 ΔOwn −7.9%

Azamian Bobak R. sold $9K of TARS, trimming their stake 8%.

−$9K

737 sh @ $12

TARS

Tarsus Pharmaceuticals, Inc.

Sell Whitfield Dianne C. · Chief Human Resources Officer · Open-market sale · filed Mar 23, 2023 ΔOwn −3.0%

Whitfield Dianne C. sold $4.2K of TARS, trimming their stake 3%.

−$4.2K

345 sh @ $12

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Mar 23, 2023 ΔOwn −7.1%

Azamian Bobak R. sold $9K of TARS, trimming their stake 7%.

−$9K

709 sh @ $13

TARS

Tarsus Pharmaceuticals, Inc.

Sell Whitfield Dianne C. · Chief Human Resources Officer · Open-market sale · filed Mar 23, 2023 ΔOwn −2.8%

Whitfield Dianne C. sold $4.2K of TARS, trimming their stake 3%.

−$4.2K

333 sh @ $13

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Mar 23, 2023 ΔOwn −6.3%

Azamian Bobak R. sold $8.8K of TARS, trimming their stake 6%.

−$8.8K

679 sh @ $13

TARS

Tarsus Pharmaceuticals, Inc.

Sell Whitfield Dianne C. · Chief Human Resources Officer · Open-market sale · filed Mar 23, 2023 ΔOwn −2.7%

Whitfield Dianne C. sold $4.2K of TARS, trimming their stake 3%.

−$4.2K

326 sh @ $13

TARS

Tarsus Pharmaceuticals, Inc.

Sell Whitfield Dianne C. · Chief Human Resources Officer · Open-market sale · filed Mar 21, 2023 ΔOwn −2.7%

Whitfield Dianne C. sold $4.2K of TARS, trimming their stake 3%.

−$4.2K

333 sh @ $13

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Mar 21, 2023 ΔOwn −6.5%

Azamian Bobak R. sold $9.3K of TARS, trimming their stake 6%.

−$9.3K

741 sh @ $13

TARS

Tarsus Pharmaceuticals, Inc.

Sell Whitfield Dianne C. · Chief Human Resources Officer · Open-market sale · filed Mar 21, 2023 ΔOwn −2.5%

Whitfield Dianne C. sold $4.2K of TARS, trimming their stake 2%.

−$4.2K

316 sh @ $13

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Mar 21, 2023 ΔOwn −6.5%

Azamian Bobak R. sold $10.6K of TARS, trimming their stake 6%.

−$10.6K

795 sh @ $13

TARS

Tarsus Pharmaceuticals, Inc.

Sell Whitfield Dianne C. · Chief Human Resources Officer · Open-market sale · filed Mar 17, 2023 ΔOwn −2.4%

Whitfield Dianne C. sold $4.2K of TARS, trimming their stake 2%.

−$4.2K

313 sh @ $13

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Mar 17, 2023 ΔOwn −6.1%

Azamian Bobak R. sold $10.6K of TARS, trimming their stake 6%.

−$10.6K

791 sh @ $13

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Mar 17, 2023 ΔOwn −0.7%

Azamian Bobak R. sold $110.3K of TARS, trimming their stake 1%.

−$110.3K

8,000 sh @ $14

TARS

Tarsus Pharmaceuticals, Inc.

Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Mar 10, 2023 ΔOwn −0.1%

Azamian Bobak R. sold $10.8K of TARS.

−$10.8K

717 sh @ $15

About TARS insider activity

This page tracks every recent Form 4 filed for Tarsus Pharmaceuticals, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is TARS insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Tarsus Pharmaceuticals, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.